Analyst Brooks O’Neil from Lake Street maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) and keeping the price target at $75.00.
Brooks O’Neil has given his Buy rating due to a combination of factors that highlight Tandem Diabetes Care’s potential for growth and value. One of the key reasons is the company’s conservative guidance, which sets a low bar for performance expectations. This cautious approach, coupled with the company’s history of outperforming its guidance, suggests a strong potential for positive surprises in future earnings.
Additionally, Tandem’s current low valuation presents a compelling investment opportunity. The stock’s significant drop in price has created a valuation gap compared to its peers, offering a chance for substantial returns as the market corrects this disparity. Furthermore, the diabetes care market remains significantly under-penetrated, particularly outside the U.S., providing a vast growth opportunity for Tandem’s innovative products. These factors, combined with the company’s strategic initiatives and market positioning, underpin O’Neil’s confidence in recommending a Buy rating.
In another report released on February 28, Barclays also maintained a Buy rating on the stock with a $53.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com